Zolbetuximab Plus EOX vs EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma
In a phase 2 trial in advanced gastric cancer with high expression of CLDN18.2, adding Ganymed Pharmaceuticals’experimental drug zolbetuximab to chemotherapy improved... Read More
